GSK Agrees to Acquire Chimagen Biosciences Trispecific T-Cell Engager Program
September 15, 2026
GSK has agreed to acquire full global rights to Chimagen Biosciences’ potential best-in-class trispecific T-cell engager program for multiple myeloma in a deal worth up to $750 million. The agreement includes an upfront payment and development and commercial milestone payments for the privately held Chimagen.
- Buyers
- GSK
- Targets
- Chimagen Biosciences
- Industry
- Pharmaceuticals
- Location
- Sichuan, China
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.